Vergelijking

Carbetocin vs. Icatibant

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

37025-55-1

138614-30-9

Molecuulmassa

geen gegevens

1304.52 g/mol

Halfwaardetijd

0.67 h

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Carbetocin

Carbetocin is an oxytocin receptor agonist with prolonged duration. It triggers a sustained contraction of the uterus after birth, preventing atonic hemorrhage — unlike oxytocin, without a multi-hour infusion.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Carbetocin	Icatibant
Duitsland	Op recept	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Carbetocin

Volledige vermelding →

Icatibant

Volledige vermelding →

Frequently asked questions

What is the difference between Carbetocin and Icatibant?: Carbetocin is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Carbetocin or Icatibant?: The highest available evidence level is "Humane RCT" for Carbetocin and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Carbetocin and Icatibant in Germany and the United States?: Duitsland: Carbetocin — Op recept, Icatibant — Op recept. Verenigde Staten: Carbetocin — Niet goedgekeurd, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Carbetocin

Icatibant

Duitsland

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Carbetocin and Icatibant?

Carbetocin is classified as "Onderzoek (overig)", while Icatibant is classified as "Onderzoek (overig)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Carbetocin or Icatibant?

The highest available evidence level is "Humane RCT" for Carbetocin and "Humane RCT" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Carbetocin and Icatibant in Germany and the United States?

Duitsland: Carbetocin — Op recept, Icatibant — Op recept. Verenigde Staten: Carbetocin — Niet goedgekeurd, Icatibant — Op recept. These are factual summaries with source and review date on the individual pages.